12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cabozantinib: Phase I data

Interim data from an open-label, dose-escalation, Japanese Phase I trial in 14 patients with advanced solid tumors showed that once-daily 40, 60 and 80 mg cabozantinib produced confirmed partial responses in 4 of 5 patients with non-small cell lung cancer (NSCLC) and 8 cases of stable disease. The MTD was once-daily 60 mg cabozantinib and...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >